NCT02824198View on ClinicalTrials.gov

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule

PHASE2CompletedINTERVENTIONAL

Enrollment

118

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

March 18, 2017

Study Completion Date

January 18, 2019

Conditions

Dengue FeverDengue Hemorrhagic Fever

Interventions

BIOLOGICAL

CYD Dengue Vaccine (5 dose formulation)

0.5 mL, Subcutaneous

BIOLOGICAL

Placebo, NaCl 0.9%

0.5 mL, Subcutaneous

Trial Locations (3)

119074

Singapore

169608

Singapore

529889

Singapore

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02824198 - Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule | Biotech Hunter | Biotech Hunter